

The Molecular Basis of Genetic Disorders Associated with Essential Elements Metabolism

The Molecular Basis of Genetic Disorders Associated with Essential Elements Metabolism

By

Rajendra Prasad

**Cambridge
Scholars
Publishing**



The Molecular Basis of Genetic Disorders Associated with Essential
Elements Metabolism

By Rajendra Prasad

This book first published 2024

Cambridge Scholars Publishing

Lady Stephenson Library, Newcastle upon Tyne, NE6 2PA, UK

British Library Cataloguing in Publication Data

A catalogue record for this book is available from the British Library

Copyright © 2024 by Rajendra Prasad

All rights for this book reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the copyright owner.

ISBN (10): 1-5275-5266-7

ISBN (13): 978-1-5275-5266-1

To

My Mentor, Prof. Ravindra Nath, and my Parents

CONTENTS

Preface	xii
Acknowledgments	xiv
List of Figures	xv
List of Tables	xix
Chapter 1	1
Biological Significance and Genetic Disorders of Copper Metabolism	
1.0 Introduction	4
1.1 Copper-dependent major biological molecules	5
1.1.1 Cytochrome c oxidase (EC-1.9.3.1)	5
1.1.2 Cu-Zn superoxide dismutase (EC-1.15.1.1)	6
1.1.3 Dopamine β -hydroxylase (EC-1.14.17, 1)	8
1.1.4 Lysyl oxidase (EC-1.4.3.13)	10
1.1.5 Peptidylglycine L-amidating monooxygenase (EC-1.14.18.1)	11
1.1.6 Tyrosinase (EC-1.14.18.1)	12
1.2 Molecular basis of copper metabolism: an overview	15
1.2.1 Copper absorption at the intestinal level	15
1.2.2 Copper export from enterocytes	16
1.2.3 Copper homeostasis in liver	16
1.2.4 Copper homeostasis in the brain	18
1.2.5 Copper storage and copper trafficking in the brain	19
1.2.6 Copper export from the brain	20
1.2.7 Copper excretion processes	20
1.3 Copper metabolism associated genetic disorders	21
1.3.1 Wilson disease (OMIM#277900)	21
1.4 Clinical manifestations of Wilson disease	27
1.4.1 Hepatic manifestations	27
1.4.2 Neurological manifestations	27
1.4.3 Neuropsychiatric manifestations	28
1.4.4 Others	28
1.5 Biochemical diagnosis of Wilson disease	28

1.5.1 Serum copper, ceruloplasmin, and non-ceruloplasmin-bound copper	28
1.5.2 Urinary copper excretion	29
1.5.3 Hepatic copper content	29
1.5.4 Kayser–Fleischer (KF) rings.....	29
1.5.5 Cu-ATPase activity.....	30
1.6 Molecular genetics of Wilson disease.....	30
1.6.1 ATP7B gene—the causal gene	30
1.6.2 ATP7B protein structure.....	31
1.6.3 Worldwide spectrum of mutations in the Cu- <i>ATP7B</i> gene.....	34
1.6.4 <i>ATP7B</i> genotype and phenotype correlation.....	35
1.6.5 Genetic factors affecting phenotypes.....	36
1.7 Treatment of Wilson disease.....	48
1.7.1 D-penicillamine	48
1.7.2 Trientine	50
1.7.3 Zinc.....	51
1.7.4 Liver transplant.....	52
1.8 Animal models for Wilson disease.....	52
1.8.1 Long Evans Cinnamon (LEC) rats	52
1.8.2 Toxic Milk (tx) Mouse	54
1.8.3 Labrador Retrievers	55
1.9 Disorders of copper metabolism associated with the Cu-ATP7A gene.....	55
1.9.1 Menkes disease (OMIM#309400)	55
1.10 Occipital horn syndrome (OMIM#304150).....	62
1.10.1 Molecular basis of OHS	63
1.10.2 Distal hereditary motor neuropathy	63
1.10.3 Treatment.....	64
1.11 Summary and future perspectives.....	64
Chapter 2.....	104
Biological Significance and Genetic Disorders of Zinc Metabolism	
2.0 Introduction	107
2.1 Zinc metabolism: an overview	108
2.1.1 Zinc homeostasis in the body	108
2.1.2 Subcellular zinc distribution.....	109
2.1.3 Zinc-accommodating intracellular vesicles/granules.....	110
2.1.4 Metallothioneins and metal transcription factor-1 (MTF-1).....	111
2.2 Biological significance of zinc	111
2.2.1 Crystal structure of insulin: its implications	111

2.2.2 Zinc metalloenzymes	112
2.2.3 Biochemistry and molecular biology of human carbonic anhydrase [EC4.2.1.1:HCA:α-CA II]	112
2.2.4 Zinc finger proteins	125
2.2.5 Metallothionine and zinc	137
2.2.6 Biochemistry and molecular biology of Zinc transporters.....	141
2.2.7 Genetic disorders associated with the presence of mutations in zinc transporters	160
2.3 Summary and future perspectives.....	168

Chapter 3..... 215

Genetic Disorders of Iron Metabolism

3.0 Introduction	217
3.1 An overview of iron metabolism	219
3.1.1 Storage of iron	221
3.1.2 Excretion.....	221
3.1.3 Bioavailability	221
3.1.4 Factors affecting dietary iron absorption.....	222
3.1.5 Regulation of iron homeostasis	224
3.1.6 Molecular basis of iron deficiency and its implications	227
3.1.7 Biochemical assessment of iron status.....	231
3.1.8 Molecular genetics of iron metabolism associated disorders.....	232
3.2 Summary and future perspectives.....	267

Chapter 4..... 303

Genetic Disorders Associated with Selenium Metabolism

4.0 Introduction	305
4.1 An Overview of selenium metabolism.....	306
4.1.1 Absorption and utilization	306
4.1.2 Inorganic selenium conversion into selenide.....	307
4.1.3 Organic selenium conversion into selenide	309
4.1.4 Bioavailability	309
4.1.5 Excretion.....	310
4.1.6 Assessment of selenium status.....	310
4.2 Biochemistry, molecular biology, and physiology of selenium	311
4.2.1 Underlying molecular mechanism of selenoprotein biosynthesis...	311
4.2.2 Regulatory mechanism of selenoprotein expression.....	319
4.2.3 Selenium genetic code	320
4.3 Selenoprotein nomenclature	321

4.3.1	Glutathione peroxidases	324
4.3.2	Glutathione peroxidase 2(GPX2)	329
4.3.3	Glutathione peroxidase 3 (GPX3)	330
4.3.4	Glutathione peroxidase 4 (GPX4)	331
4.3.5	Glutathione peroxidase 6 (GPX6)	334
4.3.6	Thioredoxin reductases [TRs].....	335
4.3.7	Thyroid hormone deiodinases.....	342
4.3.8	Selenophosphate synthetase 2 [SEPHS2]	343
4.3.9	Selenoprotein P [SELENOP].....	344
4.3.10	15KDa Selenoprotein [SELENOP]	346
4.3.11	Selenoprotein M [SELENOM]	347
4.3.12	Selenoprotein N [SELENON]	348
4.3.13	Selenoprotein K and S [SELENOK, SELENOS]	349
4.3.14	Selenoprotein W, T, H [SELENOW, SELENOT, SELENOH]....	350
4.3.15	Selenoprotein [SELENOT].....	351
4.3.16	Selenoprotein H [SELENOH]	352
4.3.17	Selenoprotein V [SELENOV]	353
4.4	General disorders associated with selenium metabolism	354
4.4.1	Spectrum of mutations in SEC1SBP2 syndrome: a disorder of thyroid hormone.....	354
4.4.2	TRU-TCAI-1 mutations	357
4.4.3	SEPSECS mutations	359
4.4.4	DIO2 SNP and TSHR mutations	361
4.4.5	DIO1 mutations	362
4.4.6	Keshan disease.....	363
4.5	Summary and future perspectives.....	364
Chapter 5.....		411
Biological Significance and Genetic Disorders of Manganese Metabolism		
5.0	Introduction	412
5.1	An overview of manganese metabolism homeostasis.....	413
5.1.1	Distribution and regulation	414
5.1.2	Liver	416
5.1.3	Bone	416
5.1.4	Kidney	417
5.1.5	Brain	417
5.1.6	Elimination	418
5.1.7	Overall Mn homeostasis regulation by different Mn transporters ..	418

5.2 Biochemistry and physiology of Mn transporters.....	420
5.2.1 Mn importers	420
5.2.2 Manganese exporters	423
5.3 Genetic disorders associated with manganese metabolism	425
5.3.1 HMNDYT-1 SLC 30A10 deficiency [OMIM#613280]	425
5.3.2 HMNDYT2-SLC39A14 deficiency [OMIM #617105]	429
5.3.3 CDG2N SLC39A8 deficiency (OMIM#616721)	431
5.4 Summary and future perspectives.....	433
 Abbreviations.....	 451
 Index	 461

PREFACE

Spectacular and far-reaching advances have been made in the knowledge related to the significance of essential elements (micronutrients) in human health and disease. Advances and breakthroughs in molecular biology, biotechnology, and molecular diagnostics have allowed us to understand more about metabolism, regulation, and functions of the micronutrients which will ultimately lead to formulations of novel strategies against specific metal related genetic disorders.

Metabolic genetic disorders associated with metals are considered classic single-gene disorders. Strikingly, the latest development in next-generation sequencing and other technologies have discovered that the classical one gene-one enzyme paradigm is not always a fact. Now, it is very clear that multiple genes may lead to the same phenotype presentation or may influence the severity of diseases. Moreover, the presence of mutations in different domains of the same protein might produce a difference in phenotype. Therefore, effective therapeutics should be considered. New advancements in DNA manipulation via clustered regulatory interspaced short palindromic repeat (CRISPR)-Cas 9 technology could be a potential future therapy in genetic disorders. The chapters of this book are comprehensively written with special reference to the molecular genetics of essential element-related disorders, which are of utmost importance in the development of precise medicine.

Molecular identification and the characterization of mutations in genes resulting from a genetic disorder are of threefold significance: (1) They help us in understanding the molecular mechanism of the disease process to formulate the therapeutic strategy. (2) They provide a DNA-based confirmatory diagnosis asymptotically. (3) The identification of the most common mutations in a genetic disorder are useful in prenatal/neonatal diagnosis. In fact, mutation analysis is the only way to distinguish the affected one from the carrier and help in genetic counseling which is the best way to eliminate the genetic disorder from the population because prevention is better than cure.

Increasingly, medical graduates and postgraduates must be equipped to integrate genetic knowledge into all areas of medicine as well as basic medical sciences in order to deliver a dimension of practice and patients care that has hitherto largely been the domain of a small breed of specialties. We have sought to provide a comprehensive basic text for those who seek a work of reference through which they can swim to calm waters, rather than one in which they will quickly drown.

To help the readers to achieve those learning goals, the text is succinctly written. Each chapter has a brief introduction of its own explaining the importance of the experiment and the historical context in which it was carried out. At the end of each chapter is a complete running summary and future perspectives to sustain enthusiasm as well as to motivate a desire to understand the basics in a comprehensive way.

In the next half-century, our understanding of how living organisms function at the molecular level, together with our ability to intervene, will expand in ways we are only beginning to perceive.

ACKNOWLEDGMENTS

I am deeply obligated to Dr. G.K. Khullar, Emeritus Professor, Department of Biochemistry, Post Graduate Institute of Medical Education and Research, Chandigarh, India, who developed rational thought and scientific temper in the budding stage of my science career as well as his continuous effort to bring forth this book in the present format.

We are grateful to the many colleagues, particularly Dr. Munish Kumar, Post Graduate Institute of Medical Education and Research, Chandigarh, India, Dr. Isha Singla, Maharishi Markandeshwar Institute of Medical Sciences and Research, Ambala, India, and Miss. Sonia Deswal at Maharishi Markandeshwar Institute of Medical Sciences and Research, Ambala, India, who generously contributed their time and effort to this project.

I particularly want to acknowledge Rebecca Gladders, Commissioning Editor, Cambridge Scholars Publishing, for her constant source of encouragement and discipline.

LIST OF FIGURES

Figure 1.1 Physicochemical properties of copper (Cu).

Figure 1.2 The overall structure of human COX.

Figure 1.3 The structure of the SOD1 dimer shows the Cu-Zn SOD sequence conservation, fold, and structural and functional regions.

Figure 1.4 Structure of the human DBH dimer.

Figure 1.5 The overall structure of human lysyl oxidase which has been shown in two perpendicular views.

Figure 1.6 The crystal structure of peptidylglycine alpha-amidating monooxygenase.

Figure 1.7 3D structures of human melanogenic proteins.

Figure 1.8 Copper homeostasis in the enterocyte.

Figure 1.9 Schematic diagram of copper transport in the body and hepatocytes.

Figure 1.10 Copper homeostasis in the brain.

Figure 1.11 Consequences of Cu-mediated toxicity in WD.

Figure 1.12 Location and structure of the *ATP7B* gene on chromosome 13.

Figure 1.13 The 3D structure of the ATP7B Protein.

Figure 1.14 Location of D13S301, D13S314 and D13S316 microsatellite markers.

Figure 1.15 Location and structure of *ATOX1* gene.

Figure 1.16 (a) Amino acid sequence of ATOX1. The amino acid sequence of ATOX1 representing MTCGGC, metal-binding site, and KKTG, the nuclear localization signal **(b)** Primary structure of ATOX1.

Human ATOX1 protein consists of 68 amino acids. **(c)** The 3D structure of ATOX1. Ribbon structure of the ATOX1 protein (PDB ID-ITL5) showing ferredoxin-like $\beta\alpha\beta\beta\alpha\beta$ - fold and location of metal-binding sites.

Figure 1.17 Location and structure of *COMMD1* gene.

Figure 1.18 (a) 3D Structure of N-domain of COMMD1 representing $\alpha 1$ - $\alpha 5$ helical structure (PDB ID- 2H2M). **(b)** Model for possible functions of COMMD1.

Figure 2.1 Diagrammatic representations of physicochemical properties of zinc.

Figure 2.2 Zinc distributions in different organs of the human body.

Figure 2.3 Mechanism of reaction.

Figure 2.4 Carbonic anhydrase genes arrangements.

Figure 2.5 Stick representation of the active site of hCAII (PDBID3D92) showing key residues that are involved in CO₂ binding and proton transfer during catalysis.

Figure 2.6 A. CAIs belonging to the zinc binders viz sulfonamides, sulfamates, carboxylates, hydroxamates, and phosphonates. The zinc-binding group [ZBG] is coordinated with the metal ion and participates in strong interactions with the gate keeper residues [Thr 199- Glu 106]. The scaffold may occupy either the hydrophilic or hydrophobic (or/both) halves of the active sites.

B. The structures of Dithiocarbamates and view of these compounds viz a) cyan b) magenta c) green, superimposed in the active site of hCA II. The zinc ion is shown as the central blue sphere.

Figure 2.7 Structure, molecular functions and subcellular localization of ZNFs.

Figure 2.8 Molecular pathways regulation by ZNFs in physiological conditions viz Keratinocytes terminal differentiation.

Figure 2.9 Transcriptional regulation of some ZNFs transcription and their roles in cancers.

Figure 2.10 Regulation of ZNFs target genes in human diseases.

Figure 2.11 Predicted general structure and function of zinc transporters viz SLC39/ZIP and SLC30/ZNT which are involved in zinc influx and efflux across the biomembranes.

Figure 2.12 Predicted topological structure of ZnT.

Figure 2.13 Predicted topological structure of ZIP transporters.

Figure 2.14 Physiological control by multiple metal transport via ZIP8 and ZIP14.

Figure 2.15 Mutations in the ZIP4 (SLC39A4) gene of acrodermatitis enteropathica.

Figure 2.16 Proposed mechanism for a corrector and a potentiator for rescuing from a pathogenic mutant of ZIP13. ZIP13 “corrector” inhibits the coordinated actions of cofactors.

Figure 3.1 Physicochemical properties of iron [Fe].

Figure 3.2 An overview of iron metabolism.

Figure 3.4 Structure of frataxin.

Figure 3.5 Mitochondria and extra-mitochondrial Fe-S cluster biogenesis.

Figure 3.6 Structural rearrangements at the zinc site of ISCU in response to binding of NFS1 and frataxin [FXN].

Figure 3.7 Amino acid sequence and secondary structure of frataxin.

Figure 3.9 Cellular mechanisms of heme biosynthesis and defects in sideroblastic anemia.

Figure 3.8 Histopathology of bone marrow and peripheral blood.

Figure 3.10 Aceruloplasminemia-associated phenotypes.

Figure 3.11 Spectrum of mutations in CP gene from aceruloplasminemia.

Figure 3.12 Simplified algorithm for diagnosis of aceruloplasminemia.

Figure 4.1 Physicochemical properties of selenium.

Figure 4.2 An overview of selenium metabolism.

Figure 4.3 Overview of the metabolic pathways and fates of the different dietary Se species and showing the central role of hydrogen selenide metabolism.

Figure 4.4 An overview of selenoprotein biosynthesis.

Figure 4.5 Cloverleaf structure of eukaryotic, archeal and bacterial tRNA^{[ser]sec}.

Figure 4.6 Mechanism of Sec biosynthesis in Eukaryotes.

Figure 4.7 Mechanism of Sec Insertion in Eukaryotes.

Figure 4.8 Structure of SECIS elements in eukaryotes (A), archaea (B), bacteria (C). Consensus structures of SECIS elements with conserved nucleotides are shown.

Figure 4.9 Crystal structure of the apo-selenocysteine-containing human GPX4 protein adapted from the data bank (PDB code: 6ELW, 129 residues, 21.91kDa).

Figure 4.10 The ferroptotic induced peroxidation of phospholipids is mediated by the cyst(e)ine/GSH/GPX/ regulatory pathway.

Figure 4.11 Elucidation of redox reactions catalyzed by sec-containing oxidoreductases.

Figure 4.12 Functional domains of SECISBP2 with the position of mutation described.

Figure 4.13 The presence of a mutation in human Sec-tRNA^{[ser]sec} in a cloverleaf model with the location of C65G mutation.

Figure 4.14 Functional domains of SEPSECS with the position of the human mutations. Schematic presentation of the human SEPSECS protein with key amino acids (above) that are part of the active domain (black bars) or interact with tRNA^{[ser]sec} (white shaded boxes and mutations described hitherto below).

Figure 4.15 Regulation of TH supply, metabolism and genomic action.

Figure 5.1 Physicochemical properties of manganese.

Figure 5.2 Schematic diagram for Mn homeostasis.

Figure 5.3 Cellular Mn transporters.

LIST OF TABLES

Table 1.1 Mutations/Polymorphisms reported in ATOX1 gene.

Table 1.2 Mutation spectrum in *COMMD1* gene.

Table 2.1 Worldwide spectrum of mutations in CAII gene and their consequences.

Table 3.1 Factors affecting iron absorption.

Table 3.2 Genetic disorders and clinical manifestations of iron overload.

Table 3.3 Effects of various variants of FXN on its interaction with NFS1 and ISCU.

Table 4.1A Selenoprotein genes named based on encoded enzymatic activity.

Table 4.1B Selenoprotein genes using the new SELENO root.

Table 5.1 Clinical characteristics of inherited manganese transporter defects.

Table 5.2 Spectrum of mutations in the SLC30A10 gene from HMNDYT1 patients.

Table 5.3 Spectrum of mutations in the SLC39A14 gene from HMNDYT2 patients.

Table 5.4 Spectrum of mutations in the SLC39A8 gene from CDG2N patients.

CHAPTER 1

BIOLOGICAL SIGNIFICANCE AND GENETIC DISORDERS OF COPPER METABOLISM

1.0 Introduction

1.1 Copper-dependent major biological molecules

1.1.1 Cytochrome c oxidase (EC-1.9.3.1)

1.1.2 Cu-Zn superoxide dismutase (EC-1.15.1.1)

1.1.3 Dopamine β -hydroxylase (EC-1.14.17, 1)

1.1.4 Lysyl oxidase (EC-1.4.3.13)

1.1.5 Peptidylglycine L-amidating monooxygenase (EC-1.14.18.1)

1.1.6 Tyrosinase (EC-1.14.18.1)

1.2 Molecular basis of copper metabolism: an overview

1.2.1 Copper absorption at the intestinal level

1.2.2 Copper export from enterocytes

1.2.3 Copper homeostasis in liver

1.2.4 Copper homeostasis in the brain

1.2.5 Copper storage and copper trafficking in the brain

1.2.6 Copper export from the brain

1.2.7 Copper excretion processes

1.3 Copper metabolism associated genetic disorders

1.3.1 Wilson disease (OMIM#277900)

1.3.1.1 Introduction

1.3.1.2 Worldwide prevalence of WD

1.3.1.3 Pathophysiology of WD

1.3.1.3.1 Copper-mediated cytotoxicity mechanisms

1.3.1.3.2 Copper-mediated hepatotoxicity

1.3.1.3.3 Copper-mediated neurotoxicity

1.3.1.3.4 Copper-mediated cytotoxicity in other organs

1.4 Clinical manifestations of Wilson disease

1.4.1 Hepatic manifestations

1.4.2 Neurological manifestations

1.4.3 Neuropsychiatric manifestations

1.4.4 Others

1.5 Biochemical diagnosis of Wilson disease

1.5.1 Serum copper, ceruloplasmin and non-ceruloplasmin-bound copper

1.5.2 Urinary copper excretion

1.5.3 Hepatic copper content

1.5.4 Kayser–Fleischer (KF) rings

1.5.5 Cu-ATPase activity

1.6 Molecular genetics of Wilson disease

1.6.1 ATP7B gene—the causal gene

1.6.2 ATP7B protein structure

1.6.3 Worldwide spectrum of mutations in the Cu-*ATP7B* gene

1.6.4 *ATP7B* genotype and phenotype correlation

1.6.5 Genetic factors affecting phenotypes

1.6.5.1 Haplotype analysis

1.6.5.2 Cu chaperones

1.6.5.2.1 ATOX1 gene

1.6.5.2.2 ATOX1 protein

1.6.5.2.3 Role of ATOX1 in copper homeostasis

1.6.5.2.4 Acquisition of Cu by ATOX1

1.6.5.2.5 Interaction of ATOX1 with ATP7B

1.6.5.2.6 Mutations in the ATOX1 gene

1.6.5.3 COMMD1

1.6.5.3.1 COMMD1 gene structure

1.6.5.3.2 COMMD1 protein structure

1.6.5.3.3 Role of COMMD1 in copper homeostasis

1.6.5.3.4 Mutations in the COMMD1 gene

1.7 Treatment of Wilson disease

1.7.1 D-penicillamine

1.7.2 Trientine

1.7.3 Zinc

1.7.4 Liver transplant

1.8 Animal models for Wilson disease

1.8.1 Long Evans Cinnamon (LEC) rats

1.8.2 Toxic Milk (tx) Mouse

1.8.3 Labrador retrievers

1.9 Disorders of copper metabolism associated with the Cu-ATP7A gene

1.9.1 Menkes disease (OMIM309400)

1.9.1.1 Copper metabolism

1.9.1.2 Molecular genetics of Menkes disease

1.9.1.3 Genotype-phenotype correlation

1.9.1.4 Molecular basis of clinical manifestation

1.9.1.5 Neurological manifestations

1.9.1.6 Diagnosis and treatment of Menkes disease

1.9.1.7 Animal models for Menkes disease

1.10 Occipital Horn Syndrome [OMIM#304150]

1.10.1 Molecular basis of OHS

1.10.2 Distal hereditary motor neuropathy

1.10.3 Treatment

1.11 Summary and future perspectives

1. Biological Significance and Genetic Disorders of Copper Metabolism

1.0 Introduction

ELEMENT INFORMATION	
Discovery year	- 9000BC
Block	- d- block
Element category	- Transition metal
Discovered by	- Middle East
Key isotopes	- ^{63}Cu
Allotropes	- None
CAS number	- 7440-50-8
Density (g cm ⁻³)	- 8.96
Electron configuration	- [Ar] 3d ¹⁰ 4s ¹

Symbol	→	Cu
Atomic number	→	29
Name	→	Copper
Atomic mass	→	63.546

Figure 1.1 Physicochemical properties of copper (Cu).

Copper is an essential element that belongs to group IIb of the periodic table. Copper is found in the free metallic state in nature. The physicochemical properties of copper are depicted in Figure 1.1. Notwithstanding, copper is an indispensable trace element in the life processes of most animals and plants, being a cofactor of various enzymes as well as binding to many important molecules to maintain structural conformations. Proteins and bioorganic molecules allow copper to play a major role in biological functions. Notably, the essential nature of copper in animals was first demonstrated by Hart *et al.* in 1928 [1, 2]. Strikingly, excess free copper, either in body fluids or intracellular, is highly toxic owing to its redox nature. Therefore, nature has provided tight regulation to maintain fine copper homeostasis at both the cellular and organism level during the time course of the evolution of organisms. A little deviation from the homeostasis leads to various copper-associated disorders. These disorders include Wilson disease, Menkes disease, occipital horn syndrome, neuropathy, Alzheimer's disease, and Parkinson's disease. In view of these facts, a better understanding of copper metabolism is of utmost importance in pathogenesis, molecular diagnosis and therapeutic aspects of various congenital disorders of copper metabolism. Thereby,

there is a need to address the biochemistry of the proteins which are involved in human copper metabolism.

1.1 Copper-dependent major biological molecules

1.1.1 Cytochrome c oxidase (EC 1.9.3.1)

Cytochrome c oxidase (COX) or complex IV of the mitochondrial respiratory chain plays a fundamental role in the energy production of aerobic cells. COX is a multimeric enzyme located in the inner mitochondrial membrane which is of dual genetic origin. Homosapien COX consists of 13 subunits. Subunits 1, 2, and 3 are large, highly hydrophobic transmembrane proteins encoded by the mitochondrial genome which form the catalytic core of the enzyme and contain metal prosthetic groups. Copper and heme form a unique heme compound found exclusively in COX with three redox, viz a Cu_A center in subunit 2, and a heme α and a Cu_B - heme α_3 binuclear center in subunit 1. The remaining subunits are small in size and are encoded by the nuclear genome. They are needed for the assembly and stability of the holoenzyme and for its dimerization.

Complex IV is the terminal enzyme of the electron transport chain, existing either as randomly scattered complexes or as a component of super complexes. NDUFA4 was previously assumed to be a subunit of complex I but recent biochemical data suggested it may be a subunit of complex IV, which is a monomer containing 14 subunits. Since NDUFA4 lies exactly at the dimeric interface in previously reported crystal structures of complex IV homodimer which preclude complex IV dimerization [3]. This complex contains three copper II ions, one magnesium ion, and one zinc ion, two heme α molecules, and several phospholipid molecules.

COX assembly and stability of fully congregated enzymes depend on the mitochondrial compartments of two partners of oxidative phosphorylation systems, the mobile electron carrier cytochrome c and the mitochondrial ATPase. It catalyzes the electron transfer from cytochrome c to di-oxygen in the final step of mitochondrial oxidative phosphorylation. The reaction occurs in concurrence with proton pumping from the matrix to intermembrane spaces resulting in the generation of a transmembrane proton gradient, which is subsequently used for the synthesis of ATP. Cytosolic copper is delivered to COX via copper chaperone CoX 17 [4]. The overall structure of COX subunits is explained in Figure 1.2 [3].





Figure 1.2 The overall structure of human COX. The subunits of COX are colored and labeled with text in the same colors. Spheres show the cofactors and phospholipids; Cardiolipin-CDL; Phosphatidylethanolamine-PEE. The two dashed lines show the transmembrane region. M-matrix; IM-inner membrane; IMS-intermembrane space [3].

1.1.2 Cu-Zn superoxide dismutase (EC 1.15.1.1)

Cu-Zn superoxide dismutase (SOD) belongs to the family of oxidoreductase known as superoxide dismutase (SOD). There are three isoenzyme forms of SOD in mammals, namely the cytosolic and extracellular, both containing Cu, and Zn at their active sites, and the mitochondrial SOD, which contains Mn at its active site. Cu-Zn SOD catalyzes the reaction between superoxide and water to yield oxygen and hydrogen peroxide.

Notably, most of the enzymes which produce and require superoxide are present in peroxisomes, for instance superoxide dismutase, catalase, and peroxidase. This reaction occurs in the following manner:



However, hydrogen peroxide (H_2O_2) is also highly toxic and needs to be detoxified. Therefore, cells use the enzyme catalase, a ubiquitous heme protein that further catalyzes the dismutation of hydrogen peroxide into water and molecular oxygen as follows:



Structurally, Cu-Zn SOD is a metalloprotein with a molecular mass of 62.913 kDa, containing both Cu and Zn ions in each subunit. The SOD protein is a dimer composed of two identical subunits that are oriented so that the two active sites are facing away from each other. Each subunit is composed of 151 amino acid residues. These amino acids are arranged in eight β -sheets and three exterior loops. Each subunit contains copper and zinc ions at the active site. Strikingly, the copper ion acts as an electron transfer center, whereas the zinc ion serves as a structural scaffold and contributes to the positive charge on the active site which attracts the negatively charged superoxide anion (Figure 1.3).




Figure 1.3 The structure of the SOD1 dimer shows the Cu-Zn SOD sequence conservation, fold, and structural and functional regions. The structural elements are coded with abbreviations: including V-loop—Variable loop; GK1 and GK2—Greek key loops 1 and 2; S-S—disulfide regions; N and C—termini. The metal-ligand residues are shown as sticks with the bridging histidine His61 in white [5].

Amyotrophic lateral sclerosis (ALS), is a disease commonly referred to as Lou Gehrig's disease and is due to the presence of mutation in the SOD1 gene. However, there is an urgent need to elucidate a better understanding

of how the spectrum of mutations in SOD causes ALS. It would be of great help to develop better diagnosis and potential therapeutics.

1.1.3 Dopamine β -hydroxylase (DBH) (EC1.14.17.1)

DBH is also known as dopamine β -monooxygenase. DBH is a copper-containing oxygenase that catalyzes the hydroxylation of the β carbon of a wide variety of phenylalanine derivatives using oxygen and ascorbate as cofactors. It belongs to a small unique class of Cu-containing hydroxylases and requires two Cu ions per unit for its activity [6, 7]. DBH is generally considered to be exclusively localized in the chromaffin granules of the adrenal medulla and sympathetic neurons of the central peripheral nervous system. It is present in the catecholamine storage vesicles, where it catalyzes the conversion of 3- and 4-dihydroxy phenylalanine (DOPA) to dopamine. Serum DBH is released from tissues with nor-adrenaline following stimulation. Reduced levels of serum DBH associated with trisomy 21 are found in Down syndrome patients. The human DBH sequence from the NCBI database with accession # PO9172 was searched for protein sequence blast. The primary structure of human DBH is 617 amino acids in length with 15 cysteine residues, of which 14 are involved in disulfide bond formation [8]. Cys154-Cys596, Cys232-Cys283, Cys269-Cys295, Cys390-Cys503, Cys394-Cys565, and Cys466-Cys488 are involved in intramolecular disulfide bonds whereas two cysteines at positions 528 and 530 are involved in intermolecular disulfide bonds. DBH is comprised of three major domains. The first major domain on the N-terminal side is the DOMON domain [7, 8]. This domain is situated from position 57 to 173 after signal sequencing. Following the DOMON domain is the copper type II ascorbate-dependent monooxygenase N-terminal domain located from position 359 to 526. The two monooxygenase domains generate the catalytic unit of the enzyme and each one binds to one Cu atom which is required for the enzyme activity. The structure of DBH is given in Figure 1.4.

EPR and EXAFS analysis of DBH protein revealed that coordination of two Cu atoms in the oxidized state produces $\text{Cu}_A(\text{His})_3(\text{H}_2\text{O})$ and $\text{Cu}_B(\text{His})_2\text{X}(\text{H}_2\text{O})$, where X is either the His or O- donor ligand or solvent (8). It has been shown that two subunits form a dimer connected through an interchain disulfide link between Cys528A-Cys528B and Cys530A-Cys530B. The DOMON domain potentially promotes tetramerization in which the substrate dopamine and potential therapeutic inhibitors nepicastat are stabilized in the active site through multiple hydrogen bonding. The DBH gene is located on the long (q) arm of the chromosome

at position 34:2 (q34.2) from 133638372-133659329 and consists of 12 exons [UniProt kB-P09172(DOPA-Human)]. A number of SNPs are known to exist within the coding amino acid sequence of the enzyme [9, 10].

Eighteen of such SNPs were studied along with their neighboring residues at a 6 Å radius of the concerned SNP. In fact, the tetramer form is known to be the active form of DBH, whilst no activity was found in the dimer or monomer form. Hence, SNPs close to the active site at the interface region of the tetramer are most harmful to DBH activity. A better understanding of the effects of these SNPs on the enzyme activity can help with the rationale of drug configuration. Strikingly, polymorphisms in the DBH gene have been reported to be associated with neurological diseases such as Parkinson's disease, Alzheimer's disease, schizophrenia and attention deficit hyperactivity disorders, which have overlapping neurological symptoms with WD [11] and ortho-static hypotension.




Figure 1.4 Structure of the human DBH dimer. The overall structure can be seen from two angles (at 90° to each other). Orange color—DOMON domain, dark green—Cu_H domain, light green—Cu_M domain, magenta—dimerization domain, gray—the interdomain regions [8].

1.1.4 Lysyl oxidase (EC 1.4.3.13)

Mammalian lysyl oxidases (LOX) are a family of copper-dependent amine oxidases, primarily involved in the remodeling of the extracellular matrix (ECM). They initiate covalent cross-linkage formation in elastin and collagen by oxidizing the peptidyl lysine of the proteins to amino adipic semialdehyde [12]. Depletion of copper using copper chelating agents from the preparations of lysyl oxidase results in the loss of enzyme activity. Hence, copper deficiency in humans leads to a reduction of cross-linking of elastin and collagen and thereby to faulty connective tissue as expressed in Menkes disease patients.

The LOX gene is mapped on the long arm of chromosome 5 with the genomic localization as 5q23.1 which consists of seven exons and six introns which are distributed across approximately 14.5 kb of genomic DNA. This gene encodes a member of lysyl oxidase family proteins by alternative splicing which generates five different LOX enzymes, namely LOX and LOX like 1-4. All these proteins are highly homologous in the catalytic C-terminal end in mammals. Notably, one of these variants is proteolytically processed to generate a regulatory pro-peptide and mature enzyme. The copper-dependent amine oxidase activity of this enzyme functions in the cross-linking of collagen and elastin while the pro-peptide plays a role in tumor suppression. Moreover, defects in this gene have been linked with a predisposition to thoracic aortic aneurysms and dissections [13].

Human lysyl oxidase is synthesized as a proenzyme of 396 amino acid residues, processed by bone morphogenetic protein-1 (BMP-1). As a result, an active form of LOX (M30KDa) and its N- terminal pro-peptide (147 residues) are produced [3]. LOX contains five disulfide bridges, a copper ion and a tyrosyl quinone cofactor. The cofactor is a quinone whose structure is derived from the cross-linking of the ϵ amino group of a peptidyl lysine with the modified side chain of a tyrosine residue and it has been designated lysine tyrosyl quinone (LTQ) [14].

Human LOX mutations Q267P, S280R, M298R, and S348R also predispose to aortic aneurysms and dissections in humans [15-17]. Besides its role in ECM assembly and architecture, LOX is overexpressed under hypoxia and is involved in cancer progression and metastasis, particularly in breast cancer metastasis to the bone via the formation of a metastatic niche [18, 19]. Targeting LOX in fibrosis and cancer may thus be a new therapeutic approach in these diseases.